- Home
- PYPD vs IMRN Comparison
PYPD vs IMRN Comparison
Compare PYPD & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- IMRN
- Stock Information
- Founded
- PYPD 2008
- IMRN 1994
- Country
- PYPD Israel
- IMRN Australia
- Employees
- PYPD 61
- IMRN N/A
- Industry
- PYPD Medical/Dental Instruments
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- PYPD Health Care
- IMRN Health Care
- Exchange
- PYPD Nasdaq
- IMRN Nasdaq
- Market Cap
- PYPD 60.4M
- IMRN 14.4M
- IPO Year
- PYPD 2020
- IMRN N/A
- Fundamental
- Price
- PYPD $3.82
- IMRN $2.10
- Analyst Decision
- PYPD Strong Buy
- IMRN
- Analyst Count
- PYPD 5
- IMRN 0
- Target Price
- PYPD $12.00
- IMRN N/A
- AVG Volume (30 Days)
- PYPD 92.7K
- IMRN 96.3K
- Earning Date
- PYPD 11-12-2025
- IMRN 08-29-2025
- Dividend Yield
- PYPD N/A
- IMRN N/A
- EPS Growth
- PYPD N/A
- IMRN N/A
- EPS
- PYPD N/A
- IMRN N/A
- Revenue
- PYPD N/A
- IMRN $4,777,422.00
- Revenue This Year
- PYPD N/A
- IMRN N/A
- Revenue Next Year
- PYPD N/A
- IMRN N/A
- P/E Ratio
- PYPD N/A
- IMRN N/A
- Revenue Growth
- PYPD N/A
- IMRN 48.63
- 52 Week Low
- PYPD $2.30
- IMRN $1.50
- 52 Week High
- PYPD $3.93
- IMRN $2.48
- Technical
- Relative Strength Index (RSI)
- PYPD 68.62
- IMRN 50.56
- Support Level
- PYPD $3.10
- IMRN $2.10
- Resistance Level
- PYPD $3.50
- IMRN $2.24
- Average True Range (ATR)
- PYPD 0.16
- IMRN 0.12
- MACD
- PYPD 0.06
- IMRN -0.02
- Stochastic Oscillator
- PYPD 96.95
- IMRN 32.50
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.